B
Banyan Biomarkers
Banyan Biomarkers | Discovery, Validation, Commercialization of Biochemical Markers
About Banyan Biomarkers
Banyan Biomarkers operates as a biotechnology firm focused on developing and commercializing objective diagnostic solutions for traumatic brain injury (TBI). The company was founded in 2002 as a spin-out from the University of Florida by a team of researchers: Dr. Ron Hayes, an expert in traumatic brain injury; Dr. Kevin Wang, a biochemist; and Dr. Nancy Denslow, a proteomics specialist. Their collective expertise led to the identification of specific protein biomarkers that are released into the bloodstream following a head injury.
The company's core product is the Banyan Brain Trauma Indicator (BTI), a blood test designed to aid in the evaluation of mild TBI, commonly known as concussions. The test measures the levels of two brain-specific protein biomarkers, UCH-L1 and GFAP, which rapidly appear in the blood within 12 hours after an injury. This provides physicians and healthcare providers with objective, quantifiable data to assess the likelihood of intracranial lesions. A significant benefit of the BTI is its ability to help rule out the need for a computed tomography (CT) scan, thereby reducing a patient's exposure to unnecessary radiation and lowering healthcare costs. Clinical studies demonstrated high accuracy, with the test predicting the presence of intracranial lesions on a CT scan 97.5% of the time and the absence of lesions 99.6% of the time.
The development of the BTI was significantly supported by funding from the U.S. Department of Defense, which sought better diagnostic tools for soldiers. A major milestone was achieved in February 2018, when the U.S. Food and Drug Administration (FDA) granted marketing clearance for the Banyan BTI, making it the first blood test approved for the evaluation of mild TBI in adults. This approval came through the FDA's Breakthrough Devices Program, which expedites the review of novel medical devices. The company's business model involves commercializing these proprietary tests for use in in-vitro diagnostics. In 2017, Banyan entered into a strategic partnership with bioMérieux, a global leader in in-vitro diagnostics, which included an equity investment and worldwide commercialization rights. Subsequently, bioMérieux acquired Banyan Biomarkers.
Source: Dealroom company dataNews
Open roles
Banyan Biomarkers in the Alachua ecosystem
The Banyan Biomarkers office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Anzu Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Banyan Biomarkers on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Banyan Biomarkers on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
